- Viruses have no cell wall and made up of nucleic acid components
- Viruses containing envelope antigenic in nature
- Viruses are obligate intracellular parasite
- They do not have a metabolic machinery of their own uses host enzymes


- Certain viruses multiply in the cytoplasm but others do in the nucleus
- Most multiplication take place before diagnosis is made

- Many antiviral drugs are *Purine* (A & G) or *Pyrimidine* (C & T) analogs.
- Many antiviral drugs are Prodrugs. They must be phosphorylated by viral or cellular enzymes in order to become active.
- Anti-viral agents inhibits active replication so the viral growth resumes after drug removal.

- Current anti-viral agents do not eliminate nonreplicating or latent virus
- Effective host immune response remains essential for the recovery from the viral infection
- Clinical efficacy depends on achieving inhibitory conc. at the site of infection within the infected cells

Stages of viral replication

- Cell entry Attachment
 - Penetration
- Uncoating
- Transcription of viral genome
- Translation
- Assembly of virion components
- Release



Anti-herpes virus agents

- Acyclovir / Valacyclovir
- Famciclovir / Penciclovir
- Ganciclovir / Cidofovir
- Foscarnet
- Trifluridine / Idoxuridine / Vidarabine

Acyclovir & related compounds:


- Valacyclovir is a prodrug of Acyclovir with better bioavailability.
- Famciclovir is hydrolyzed to Penciclovir and has greatest bioavailability.
- Penciclovir is used only topically whereas Famciclovir can be administered orally.

Pharmacology of acyclovir and related compounds

• Acyclovir, Valacyclovir, Ganciclovir, Famciclovir, Penciclovir all are guanine nucleoside analogs.

Mechanism of action of Acyclovir and related compounds :

- All drugs are phosphorylated by a viral thymidine-kinase, then metabolized by host cell kinases to nucleotide analogs.
- The analog inhibits viral DNA-polymerase
- Incorporation of acyclovir triphosphate into the growing viral DNA chain
- Only actively replicating viruses are inhibited



- Acyclovir is thus selectively activated in cells infected with herpes virus.
- Uninfected cells do not phosphorylate acyclovir.

Antiviral spectrum : Acyclovir: HSV-1, HSV-2, VZV, Shingles. Ganciclovir / Cidofovir : CMV • Famciclovir : Herpes genitalis and shingles Foscarnet : HSV, VZV, CMV, HIV Penciclovir : Herpes labialis Trifluridine : Herpetic keratoconjunctivitis

Pharmacokinetics of Acyclovir :

- Oral bioavailability ~ 20-30%
- Distribution in all body tissues including CNS
- Renal excretion: > 80%
- Half lives: 2-5 hours
- Administration: Topical, Oral, IV

Adverse effects of Acyclovir / Ganciclovir

- Nausea, vomiting and diarrhea
- Nephrotoxicity crystalluria, haematuria, renal insufficiency
- Myelosuppression Neutropenia and thrombocytopenia Ganciclovir

Therapeutic uses :

Acyclovir is the drug of choice for:

- HSV Genital infections
- HSV encephalitis
- HSV infections in immunocompromised patient

Ganciclovir is the drug of choice for:

- CMV retinitis in immunocompromised patient
- Prevention of CMV disease in transplant patients

Cidofovir :

- It is approved for the treatment of CMV retinitis in immunocompromised patients and Adenovirus infections
- It is a nucleotide analog of cytosine no phosphorylation required.
- It inhibits viral DNA synthesis
- Available for IV, Intravitreal inj, topical
- Nephrotoxicity is a major disadvantage.

PHARMACOLOGY OF VIDARABINE

• Vidarabine is a nucleoside analog. (adenosine)

Antiviral spectrum of Vidarabine : HSV-1, HSV-2 and VZV.

Its use is limited to HSV keratitis only

Vidarabine

- The drug is converted to its triphosphate analog which inhibits viral DNA-polymerase.
- Oral bioavailability ~ 2%
- Administration: Ophthalmic ointment
- Used in HSV keratoconjunctivitis in immunocompromised patient.
- Anemia and SIADH are adverse effects.

PHARMACOLOGY OF TRIFLURIDINE

• Trifluridine is a Pyrimidine (C, T) nucleoside analogs - inhibits viral DNA synthesis.

Antiviral spectrum Trifluridine :

- HSV-1, HSV-2 and VZV.
- Use is limited to Topical Ocular HSV Keratitis

PHARMACOLOGY OF FOSCARNET

- Foscarnet is an inorganic pyrophosphate analog
- It directly inhibits viral DNA and RNA polymerase and viral reverse transcriptase (it does not require phosphorylation for antiviral activity)

Foscarnet

- HSV-1, HSV-2, VZV, CMV and HIV.
- Oral bioavailability ~ 10-20%
- Distribution to all tissues including CNS
- Administration: IV

Therapeutic uses of Foscarnet

- It is an alternative drug for
- HSV infections (acyclovir resistant / immunocompromised patient)
- CMV retinitis (ganciclovir resistant / immunocompromised patient)

Respiratory viral infections Influenza –

- Amantadine / Rimantadine
- Oseltamivir / Zanamavir (Neuraminidase inhibitors)


RSV bronchiolitis –

• Ribavirin

Amantadine and Rimantadine : Influenza

- Prevention & Treatment of influenza A
- **Inhibition of viral uncoating** by inhibiting the viral membrane protein M2
- Influenza A virus only

Amantadine and Rimantadine: Mechanism of Action



- Blocks M2 protein channel (type A only)
- Disrupts hydrogen transport, viral uncoating in host cell and therefore viral RNA transcription

Pharmacokinetics of Amantadine

- Oral bioavailability ~ 50-90%
- Amantadine cross extensively BBB whereas Rimantadine does not cross extensively .
- Administration: Oral

Neuraminidase inhibitors : Influenza A & B Oseltamivir / Zanamavir

- Influenza contains an enzyme *neuraminidase* which is essential for the replication of the virus.
- *Neuraminidase inhibitors* prevent the release of new virions and their spread from cell to cell.

Neuraminidase inhibitors : Influenza Oseltamivir / Zanamavir

- These are effective against both types of influenza A and B.
- Do not interfere with immune response to influenza A vaccine.
- Can be used for both prophylaxis and acute treatment.

Anti-viral drugs Neuraminidase inhibitors : Influenza Oseltamivir / Zanamavir

- Oseltamivir is orally administered.
- Zanamavir is given intranasal.
- Risk of bronchospasm with zanamavir

PHARMACOLOGY OF RIBAVIRIN

- **Ribavirin** is a guanosine analog.
- Requires phosphorylation to mono-, di- and triphosphate
- Triphosphate Inhibits RNA polymerase and depletes cellular stores of guanine (inhibit IMDH)
- Decrease synthesis of mRNA 5' cap (interfere with guanylation and methylation of nucleic acid base)

Antiviral spectrum : RNA viruses are susceptible, including influenza, parainfluenza viruses, **RSV**, Lassa virus

Ribavirin : RSV

- Distribution in all body tissues, except CNS
- Administration : Oral, IV, Inhalational in RSV.
- Anemia and jaundice are adverse effects
- Not advised in pregnancy.

Therapeutic uses Ribavirin *Ribavirin is the drug of choice for:*


- RSV bronchiolitis and pneumonia in hospitalized children (given by aerosol)
- Lassa fever

Ribavirin is an alternative drug for:

• Influenza, parainfluenza, measles virus infection in immunocompromised patients

Hepatic Viral infections :

- Interferons
- Lamivudine cytosine analog HBV
- Entecavir guanosine analog HBV lamivudine resistance strains
- Ribavirin Hepatitis C (with interferons)



(From Dorland's illustrated medical dictionary, ed 30, Philadelphia, 2003, Saunders.)

Fig. 39-2. Human immunodeficiency virus (HIV). Within the core capsid, the diploid, single-stranded, positive-sense RNA is complexed to nucleoprotein.

HAART - Highly active antiretroviral therapy

- Includes at least three medications
 - "cocktails"
- These medications work in different ways to reduce the viral load

- <u>Reverse transcriptase inhibitors (RTIs)</u>
 - Block activity of the enzyme reverse transcriptase, preventing production of new viral DNA
- Reverse transcriptase inhibitors (RTIs)
 - Nucleoside RTIs (NRTIs): Azidothymidine (AZT), Didanosine (ddI), Stavudine (D4T), Lamivudine (3TC)
 - Nonnucleoside RTIs (NNRTIs): Nevirapine, delavirdine, efavirenz
 - Nucleotide RTIs (NTRTIs):Tenofovir, Adefovir

Nucleoside RTIs (NRTIs):

Azidothymidine (AZT), Didanosine (ddI), Stavudine (D4T), Lamivudine (3TC)

- Requires phosphorylation by host cellular enzymes (kinases) to their active triphosphate form
- Selective theraputic effect: HIV RT is more sensitive to AZT than is host cell DNA polymerase

3TC (lamivudine/Epivir)



- Toxicity
 - Few
 - Hepatitis B exacerbation
- Side Effects
 - Few; class effect
- Dosing
 - 150mg bid or
 - 300mg qd
 - Renal dosing available
- Special Considerations
 - Hepatitis B
- Combination with AZT

D4T (stavudine/Zerit)



- Toxicity
 - Lipoatrophy
 - Peripheral neuropathy
 - Pancreatitis
 - Lactic acidosis
- Side Effects
 - Gen well-tolerated
 - H/N/V
- Dosing
 - 40mg bid (if >60kg)
 - 30mg bid (if <60kg)</p>
- Combination only

AZT (zidovudine/Retrovir)



- Toxicity
 - Anemia
 - Neutropenia
 - Thrombocytopenia
 - Myopathy
- Side Effects
 - Nausea/vomiting
 - Headache
 - Dizziness
- Dosing
 - 300mg bid
- Combination only

DDI (didanosine/Videx)



- Toxicity
 - Lactic acidosis
 - Peripheral neuropathy
 - Pancreatitis
 - Lipodystrophy
- Side Effects
 - GI
- Dosing
 - If EC, 400mg QD (<60kg: 250mg qd)
 - If reg tabs, 200mg bid (<60kg:125 bid/250qd)
 - Empty stomach
- Combination only

Nonnucleoside RTIs (NNRTIs): Nevirapine, delavirdine, efavirenz

- Active against HIV-1
- Do not require cellular enzymes to be phosphorylated
- Do not inhibit human DNA polymerase
- Relatively safe: noncytotoxic
- Highly prone to drug resistance
- Used in combination with other drugs active against HIV

Protease inhibitors (PIs)

- Inhibit the protease retroviral enzyme, preventing viral replication
- Inhibition of this enzyme blocks viral assembly and release
- <u>Examples:</u>
 amprenavir (Agenerase)
 nelfinavir (Viracept)
 saquinavir (Invirase)

indinavir (Crixivan) ritonavir (Norvir)

- Hepatotoxic
- Used in combination with other drugs active against HIV

• Fusion inhibitors

- Inhibit viral fusion, preventing viral replication
- Newest class of antiretroviral drugs
- Example: enfuvirtide (Fuzeon)
- Used in combination with other drugs active against HIV
- Side effects:
 - peripheral neuropathy, insomnia, depression, cough, dyspnoea, anorexia, arthralgia

<u>Entry inhibitor</u>

- Inhibit viral entry into macrophages a T-cells
- CCR5 receptor antagonist
- FDA approved in 2007
- Maraviroc (Selzentry, or Celsentri outside the U.S)
- Used in combination with other drugs active against HIV
- HIV can also use other coreceptors, such as CXCR4, an HIV tropism test such as a trofile assay must be performed to determine if the drug will be effective
- Safety issues regarding blocking CCR5, a receptor whose function in the healthy individual is not fully understood

• Combinations of multiple antiretroviral medications are common

• Adverse effects vary with each drug and may be severe-monitor for dose-limiting toxicities

• Monitor for signs of opportunistic diseases

Interferons

- **Interferons** (IFNs) are natural proteins produced by the cells of the immune systems in response to challenges by foreign agents such as viruses, bacteria, parasites and tumor cells.
- Antiviral, immune modulating and anti-proliferative actions
- Three classes of interferons $-\alpha$, β , γ

Interferons

- α and β interferons are produced by all the cells in response to *viral infections*
- γ interferons are produced only by T lymphocyte and NK cells in response to cytokines – *immune regulating effects*
- γ has less anti-viral activity compared to α and β interferons

Mechanism of action of Interferons :

- **Induction** of the following enzymes:
- 1) a protein kinase which inhibits protein synthesis
- 2) an oligo-adenylate synthase which leads to degradation of viral mRNA

 3) a phosphodiesterase which inhibit t-RNA
 The action of these enzymes leads to an inhibition of translation

Antiviral spectrum : Interferon α

- Includes HBV, HCV (Pegylated interferon) and HPV.
- addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form
- Anti-proliferative actions may inhibit the growth of certain cancers like Kaposi sarcoma and hairy cell leukemia.

Pharmacokinetics : Interferons

- Oral bioavailability: < 1%
- Administered Intralesionally, S.C, and I.V
- Distribution in all body tissues, except CNS and eye.
- Half lives: 1-4 hours

Adverse effects of Interferons

- Acute flu-like syndrome (fever, headache)
- Bone marrow suppression (granulocytopenia, thrombocytopenia)
- Neurotoxicity (confusion, seizures)
- Cardiotoxicity arrhythmia
- Impairment of fertility

Therapeutic uses Interferons

- Chronic hepatitis B and C (complete disappearance is seen in 30%).
- HZV infection in cancer patients (to prevent the dissemination of the infection)
- CMV infections in renal transplant patients
- Condylomata acuminata (given by intralesional injection). Complete clearance is seen ~ 50%.
- Hairy cell leukemia (in combination with zidovudine)
- AIDS related Kaposi's sarcoma

Virus	Diseases	Drug(s) of choice	Alternative drugs
FLU A	Influenza	Amantadine	Rimantadine
RSV	Pneumonia, bronchiolitis	Ribavirin (aerosol)	
HSV	Genital herpes	Acyclovir	Foscarnet
	Keratitis Conjunctivitis	Trifluridine	Idoxuridine Vidarabine
	Encephalitis	Acyclovir	
	Neonatal HSV infection	Acyclovir	Vidarabine
	Herpes infections in immuno- compromised host	Acyclovir	Foscarnet

VZV	In normal host	No therapy	
	In immunocompro- mised host, or during pregnancy	Acyclovir	Foscarnet
CMV	Retinitis	Ganciclovir	Foscarnet
HIV	AIDS HIV antibody positive with CD4 count < 500/mm ³	Zidovudine ± protease inhibitors	Didanosine, Stavudine
HBV HCV	Hepatitis B, C	Interferons	